The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men
about
Profile of brivaracetam and its potential in the treatment of epilepsyBrivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base[Brivaracetam for add-on treatment in focal epilepsy].Emerging drugs for partial-onset epilepsy: a review of brivaracetamDrug interactions involving the new second- and third-generation antiepileptic drugs.New developments in the management of partial-onset epilepsy: role of brivaracetam.Emerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Brivaracetam for the treatment of epilepsy in adults.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Evaluation of brivaracetam: a new drug to treat epilepsy.Brivaracetam for the treatment of epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam: First Global Approval.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.Brivaracetam disposition in mild to severe hepatic impairment.Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.Research and Education.Effect of brivaracetam on CYP3A activity, measured by oral midazolam.Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.Pharmacological interactions between brivaracetam and ethanol in healthy males.Brivaracetam: a novel antiepileptic drug for focal-onset seizures.A review of the pharmacology and clinical efficacy of brivaracetam.Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women.
P2860
Q26776317-99155B50-789C-476F-90F2-9D597370D58EQ28076065-87CB3F23-763B-42F2-A38A-02C215A957CFQ30390285-05ECA118-22B8-40EB-B1B1-5C68643BA07EQ36891212-35F1CBBF-AAF4-44E4-BEA3-9885F7987947Q37658910-80BF6C7D-69BA-4E6A-A1AD-41ADA2ACC727Q37693757-720779D3-D7C0-46A0-9B9F-9288AEDC9A6DQ37754477-9D558CD7-F919-4007-9F2E-3C2426EA19FBQ37831297-4C553255-AA42-4E51-977E-209F97C0C7B2Q38195636-0A01F349-CC73-4071-8274-D41EA4F0DE5CQ38614499-BBB10502-20A5-451D-A8E9-9CD7911A285EQ38626838-BABB5945-4CB7-4C40-AE7D-E015C7D629CBQ38652806-91C6CA40-9CFD-43DC-A926-7E219624C7D1Q38694479-27E49DA7-DD50-4CB3-9384-D1DF55B0B671Q38739649-81161F48-D987-479C-89B1-B1E050625606Q38743281-66145BE4-B5BD-4EEE-93E9-D764E3CFD6CDQ38752407-ADDE6565-675C-44BC-A337-FCF124F3DCE5Q38915714-4DF9A4C6-7F9B-4E70-BCB8-49088159FDB7Q38944443-0C4BE0F2-DF7D-4140-B13D-C00772D0D495Q38985697-638E2052-BFBA-42D8-B70F-13CD24A86EB3Q39794501-B903DF93-9719-44AF-AFEC-32251865AD9EQ39899497-C5B710C3-216D-4099-BA6C-B41302E25192Q40215881-C6FA44E7-7232-4033-B2AC-6AE0EFC40641Q44231616-96EE776F-0D9A-4C76-8625-E2416CCEE4AFQ44773924-3E1A7D10-0748-4D59-940A-8623F29476B8Q45762885-0DE4314C-B0D4-45DC-AF9E-A9D30990750CQ47774665-BA67672F-E959-4DB1-838B-9D4DA7628ED1Q47853821-38E0AFBD-E0D2-4C9F-AA69-D624B43295B4Q48130509-54B7BEC9-F07F-4100-9FFF-05BAAFB2EB4CQ48596485-D35184C9-E0FD-4DFE-B15F-379A992468A4Q49253776-CE8200AF-E346-4E6F-9B73-AD480622E66EQ49700507-911EFED5-4BA0-4CD4-94B8-B2AB5BCB8F58Q51771465-566845A8-FDDA-47A8-9C68-EFF520C2F363Q53073031-F0C869A0-291A-4120-A577-4368FAA168C1Q54375873-6D5BB1C2-A368-4D4C-8B4C-C9EC5006B7C6
P2860
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@ast
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@en
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@nl
type
label
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@ast
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@en
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@nl
prefLabel
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@ast
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@en
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@nl
P2093
P2860
P3181
P1476
The pharmacokinetics, CNS phar ...... sing oral doses in healthy men
@en
P2093
Armel Stockis
Etienne Pigeolet
Maria Laura Sargentini-Maier
Paul Rolan
P2860
P3181
P356
10.1111/J.1365-2125.2008.03158.X
P407
P577
2008-07-01T00:00:00Z